FDA grants accelerated approval to Inovio's DNA immunotherapy Voceryq for rare HPV-linked airway disease
The first DNA-based therapy approval marks a shift in the field from vaccines toward therapeutic use in recurrent respiratory papillomatosis.
Read at Fierce Pharma →Full coverage · 13 outlets
- Fierce Pharma · lead
- BioPharm InternationalFDA Grants Accelerated Approval to Inovio DNA Immunotherapy for RRP
- Endpoints NewsUniQure gets review date and adcomm; Inovio’s stock surges after approval
- The Pharma LetterInovio rockets as it wins FDA approval of Voceryq
- ChosunbizFda grants first dna therapy approval, shifting focus from vaccines to treatment
- MedPage TodayNovel Therapy Lands Speedy Approval for Wart-Like Airway Disease
- Medical DailyNew DNA-based therapy offers adults with recurrent HPV airway disease an alternative to repeated surgeries
- Pharmacy TimesFDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
- BioSpaceINOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
- MedCity NewsInovio’s DNA-Based Immunotherapy Lands Speedy FDA Nod for Rare Type of Tumor
- BigGo FinanceFDA Clears First DNA-Based Therapy, Inovio's Voceryq, for Rare Airway Disease
- DealroomInovio wins FDA accelerated approval for Voceryq, first DNA immunotherapy for rare airway disease RRP
- StreetinsiderFDA grants accelerated approval to Inovio's VOCERYQ for rare airway disease